10:09 AM EDT, 07/09/2025 (MT Newswires) -- Evoke Pharma ( EVOK ) shares soared 171% in recent Wednesday trading after the company said it received a notice of allowance from the US Patent and Trademark Office for a patent application covering the use of Gimoti in patients displaying moderate to severe symptoms of gastroparesis.

Once issued, the patent is expected to expire in December 2036, and the company intends to list it in the FDA's Orange Book, extending market exclusivity for Gimoti beyond other existing patents.

Gimoti is an FDA-approved, non-oral, self-administered formulation of metoclopramide indicated for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Price: 7.21, Change: +4.55, Percent Change: +171.05